Jefferies Initiates Oncothyreon With Buy

Analysts at Jefferies initiated coverage on

with a Buy rating. The target price for Oncothyreon is set to $2.50. Oncothyreon shares have dropped 56.81% over the past 52 weeks, while the S&P 500 index has gained 10.50% in the same period. Oncothyreon's shares climbed 6.33% to close at $1.68 yesterday.